Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV001018786 | SCV001180063 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-11-14 | criteria provided, single submitter | clinical testing | The c.314_315delGCinsCA variant (also known as p.G105A), located in coding exon 3 of the TP53 gene, results from an in-frame deletion of GC and insertion of CA at nucleotide positions 314 to 315. This results in the substitution of the glycine residue for an alanine residue at codon 105. Functional data is not available for this alteration in the IARC TP53 database; however, a missense alteration which results in the same amino acid substitution, c.314G>C (p.G105A), is in the DNA binding domain of the TP53 protein and is reported to have partial loss of transactivation in yeast based assays (IARC TP53 database: Kato S et al. Proc. Natl. Acad. Sci. USA 2003 Jul;100:8424-9). Studies conducted in human cell lines indicate the c.314G>C (p.G105A) alteration is deficient at growth suppression (Kotler E et al. Mol. Cell 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). The c.314G>C (p.G105A) alteration has been reported as a somatic mutation once in a tumor, but not as a germline mutation by the IARC TP53 database (Bouaoun L et al. IARC TP53 database [version 20, July 2019]. Hum. Mutat. 2016 Sep;37:865-76). This amino acid position is highly conserved in available vertebrate species. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |